Becton Dickinson マネジメント

マネジメント基準チェック /34

Becton Dickinsonの CEO はTom Polenで、 Apr2017年に任命され、の在任期間は 7.5年です。の年間総報酬は$ 17.31Mで、 7.6%給与と92.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.02%を直接所有しており、その価値は€ 12.88M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と7年です。

主要情報

Tom Polen

最高経営責任者

US$17.3m

報酬総額

CEO給与比率	7.6%
CEO在任期間	7.5yrs
CEOの所有権	0.02%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	7yrs

経営陣の近況

Recent updates

CEO報酬分析

Becton Dickinson の収益と比較して、Tom Polen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	US$17m	US$1m	US$1b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m

報酬と市場: Tomの総報酬 ($USD 17.31M ) は、 German市場 ($USD 5.06M ) の同規模の企業の平均を上回っています。

報酬と収益: Tomの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Tom Polen (51 yo)

7.5yrs

在職期間

US$17,309,938

報酬

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thomas Polen	President	7.5yrs	US$17.31m	0.020% € 12.9m
Christopher DelOrefice	Executive VP & CFO	3.1yrs	US$5.21m	0.0044% € 2.8m
Shana Neal	Executive VP & Chief People Officer	2.5yrs	US$5.89m	0.0057% € 3.6m
Michael Garrison	Executive VP & President of Medical segment	2.1yrs	US$3.65m	0.0019% € 1.2m
Thomas Spoerel	Senior VP	5yrs	データなし	0.00071% € 448.8k
Elizabeth McCombs	Executive VP & Chief Technology Officer	3.5yrs	データなし	データなし
Joseph Smith	Senior VP	2.9yrs	データなし	データなし
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	2.8yrs	データなし	データなし
Greg Rodetis	Head of Investor Relations	less than a year	データなし	データなし
Michelle Quinn	Executive VP & General Counsel	1.7yrs	データなし	0.0017% € 1.1m
Claudia Curtis	Senior VP	no data	データなし	データなし
Carla Burigatto	Senior VP & Chief Communications Officer	no data	データなし	データなし

2.8yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: BOXの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Polen	President	4.8yrs	US$17.31m	0.020% € 12.9m
Joseph Smith	Senior VP	2.9yrs	データなし	データなし
John DeFord	Co-Chair of Scientific Advisory Board	3.4yrs	データなし	データなし
Robert Eckert	Independent Director	8.1yrs	US$362.77k	0.0028% € 1.8m
Timothy Ring	Independent Director	7.8yrs	US$332.78k	0.020% € 12.9m
Jeffrey Henderson	Independent Director	6.2yrs	US$357.78k	0.0019% € 1.2m
Christopher Ian Jones	Independent Director	14.3yrs	US$362.78k	0.0074% € 4.7m
Bertram Scott	Lead Independent Director	22.1yrs	US$372.78k	0.012% € 7.7m
Catherine Burzik	Independent Director	11.8yrs	US$357.78k	0.0046% € 2.9m
William Brown	Independent Director	2.7yrs	US$332.78k	0.00087% € 550.0k
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	17.9yrs	US$340.15k	0.0078% € 5.0m
Carrie Byington	Independent Director	3yrs	US$337.78k	0.00099% € 625.8k

7.0yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: BOXの取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

Becton Dickinson マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Recent updates

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Now 21% overvalued after recent price rise

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Now 21% overvalued

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Upcoming dividend of US$0.95 per share

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Upcoming dividend of US$0.95 per share

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Fourth quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

Upcoming dividend of US$0.95 per share at 1.6% yield

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Now 21% undervalued after recent price drop

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Upcoming dividend of US$0.91 per share at 1.3% yield

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Upcoming dividend of US$0.91 per share at 1.5% yield

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released

Now 20% undervalued after recent price drop

Upcoming dividend of US$0.91 per share at 1.6% yield

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Upcoming dividend of US$0.91 per share

Full year 2022 earnings released: EPS: US$5.42 (vs US$6.92 in FY 2021)

Full year 2022 earnings released: EPS: US$5.42 (vs US$6.92 in FY 2021)

マネジメント基準チェック /34